CompletedNCT01855074
Long-Acting Risperidone for Schizophrenia-Spectrum Conditions
About this title
Read the official source — NCT01855074This study evaluated the safety and effectiveness of Risperidone for people with schizophrenia.
Medication studyAges 18+
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Risperidone for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
What did participation involve?
The study group receives risperidone as a study medication.
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNovember 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 80
- Sponsor
- Janssen-Cilag Ltd.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Not clearly listed
- Age range
- Over 18 Years
- Official registry ID
- NCT01855074
- Official title
Show the full official title
Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedLocations not listed
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Risperidone for people with schizophrenia.
Who is behind this study?
The study sponsor is Janssen-Cilag Ltd.
Did this study involve medication?
Yes. The study involved medication, including Risperidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia